AbbVie stock ends the day slightly higher at the close on Nasdaq
Published on 09/21/2026 at 23:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock closed at USD 263.96 on the Nasdaq on September 21, 2026, gaining roughly 0.5 percent from the prior close and keeping the shares near their recent highs. Compared with its 52-week high of about USD 267.47, the stock finished the day only a few dollars below that level, underscoring the market’s upbeat view on the drugmaker.
September 21, 2026 in numbers
AbbVie Inc. (ISIN US00287Y1091, Nasdaq: ABBV) was reported to have opened the session close to USD 263 on the Nasdaq and traded within a daily range between roughly USD 262 and USD 266, leaving the close well inside that band per quote data referenced by Ad-hoc-news. Per the same overview, the move left AbbVie modestly above a 52-week low around USD 190.75 while still short of the 52-week high near USD 267.47, so the stock spent the day trading toward the upper end of its one-year range.
For context, AbbVie’s advance of about 0.5 percent on September 21, 2026 slightly outpaced the broader U.S. market, with the S&P 500 index reported up around 0.4 percent that day in company news coverage from Investing.com. That left AbbVie continuing to trade close to its recent highs after a strong multi-month run, with the stock noted as having gained strongly over the past six months in a separate company-news brief at Investing.com.
After the bell and the next trading day
After the close on September 21, 2026, attention in AbbVie centered on a newly announced AI drug discovery collaboration with Iambic, which was highlighted as a key positive driver for the shares by both Ad-hoc-news and Investing.com. With no major earnings or dividend events scheduled immediately after the bell, trading in the extended session is likely to be shaped mainly by follow-through on this collaboration news and broader healthcare sentiment heading into the next U.S. trading day on September 22, 2026.
